Ex-Synthes employee fights back in generic device tussle

Synthes is fighting an ex-employee in court alleging, among other things, illegal use of proprietary information. John Marotta is trying to make generic medical devices--and he may have hit on a good business model. "The payers are moving in our direction," said Marotta, CEO of Emerge Medical and former Synthes sales consultant. "If you have a $6,000 total knee replacement and a $3,000 total knee replacement that is substantially equivalent, with the same clinical outcome, the market will choose the $3,000 knee." And this week, his attorney decided to fight back, filing a counterclaim in federal court accusing Synthes of antitrust violations, making misleading statements and trying to crush Emerge through litigation. Item

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.